Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients from a well‐defined region
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14072 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Maria L Andersson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Atrial Fibrillation, Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancerfonden, Insamlingsstiftelsen Cancer-och Allergifonden, Stockholms Läns Landsting.
Abstract (Originalsprache)
Objective
Ibrutinib treatment is associated with cardiovascular side effects, in particular atrial fibrillation (AF) and hypertension, as well as increased risk of bleeding. Here, we aimed at describing the incidence of these events during long‐term follow‐up in patients with chronic lymphocytic leukemia treated outside clinical trials as well as identifying clinical factors predictive of developing AF. Additionally, other reasons for treatment withdrawal were analyzed.
Methods
The study was retrospective, data were collected from medical records.
Results
A total of 134 patients were identified. Median follow‐up was 32 months (range 3–103) and median duration of ibrutinib treatment was 26 months (range 1–103). Of 110 patients with no prior history of AF, 24.5% were diagnosed during treatment. Newly diagnosed or worsening of pre‐existing hypertension occurred in 15.7%. Sixty‐six % of the patients experienced bleeding events, of which 7.5% grade 3–4. Treatment discontinuation and dose reduction occurred in 68% and 47% of the patients, respectively, mostly due to toxicity.
Conclusions
The incidence of AF was high and at a median follow‐up of 2.5 years, two‐thirds of the patients discontinued treatment mostly due to bleeding and infections. Treatment‐related toxicity of any grade should be regarded as a concern of prolonged ibrutinib therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Hematology, Lymphoma Unit, Karolinska University Hospital, Stockholm, Sweden.
- Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Lotta Hansson
Förderung
- Cancerfonden
- Insamlingsstiftelsen Cancer-och Allergifonden
- Stockholms Läns Landsting
- Swedish Blood Cancer Foundation
- Swedish Cancer Foundation
- Swedish Cancer Society
- Stockholm County Council
Zitieren
APA
Andersson, M. L., Johansson, H., Österborg, A., Månsson-Broberg, A., Hansson, L., & Palma, M. (2023). Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients from a well‐defined region. European Journal of Haematology. https://doi.org/10.1111/ejh.14072
Vancouver
Andersson ML, Johansson H, Österborg A, Månsson-Broberg A, Hansson L, Palma M. Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients from a well‐defined region. European Journal of Haematology. 2023. doi:10.1111/ejh.14072
BibTeX
@article{Andersson2023,
author = {Andersson, Maria L and Johansson, Hemming and Österborg, Anders and Månsson-Broberg, Agneta and Hansson, Lotta and Palma, Marzia},
title = {Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients from a well‐defined region},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14072}
}
EUVIMED